NovoCure: There Is Still More Upside [Seeking Alpha]
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Seeking Alpha
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top of a strong core business that has beat growth expectations. With downside risks limited to execution or FDA recall, and a price target of $35.10, I raise my rating from buy to strong buy. wildpixel I am updating my analysis on NovoCure Limited (NASDAQ: NVCR ) in light of FDA approval of its lung cancer treatment and the resulting price action. I previously rated NovoCure a buy for the following reasons: Quarterly results exceeded my expectations with higher revenue growth and aggressive cost management Market tailwinds in the speciality oncology space were accelerating Approved treatments in the core business were continuing to succeed DCF generated price target of $22.10 was 46% upside from today's pricing. Since then, Novocure has risen 34% versus the S&P 500 at 1
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma [Yahoo! Finance]Yahoo! Finance
- Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in GlioblastomaBusiness Wire
- FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for GlioblastomaBusiness Wire
- NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
NVCR
Earnings
- 10/30/24 - Beat
NVCR
Sec Filings
- 11/6/24 - Form 4
- 11/4/24 - Form 4
- 11/4/24 - Form 4
- NVCR's page on the SEC website